MedPath

Left vs. Right Non-Inferiority Trial

Not Applicable
Recruiting
Conditions
Major Depressive Disorder
Depression
Major Depressive Episode
Interventions
Device: Repetitive Transcranial Magnetic Stimulation
Device: Low Frequency Right (LFR)
Device: Intermittent Theta Burst Stimulation (iTBS)
Registration Number
NCT04999553
Lead Sponsor
University of British Columbia
Brief Summary

The aim of this study is to test the hypothesis that low-frequency rTMS (LFR) works as well as the established intermittent thetaburst rTMS (iTBS) treatment for treatment resistant depression (TRD).

Detailed Description

In this multi-centre, triple-blinded, non-inferiority trial 420 patients with TRD will be recruited at two academic centres (UBC, CAMH). Patients will be randomised to receive either iTBS or LFR for 30 sessions. The primary outcome will be the improvement on a depression scale. Secondary outcome will be improvement of suicidal ideation. A secondary aim is to test the predictive capacity of a novel, easy to implement heart rate based biomarkers (i.e. heart rate variability).

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
420
Inclusion Criteria
  1. are female or male;
  2. are outpatients;
  3. are voluntary and competent to consent to treatment;
  4. have a DSM 5 diagnosis of MDD,55 single or recurrent confirmed by Mini-International Neuropsychiatric Interview (MINI) version 7.0;
  5. are 18yo to 65yo;
  6. have failed to achieve a clinical response to an adequate dose of an antidepressant based on an Antidepressant Treatment History Form (ATHF) score of > 3 in the current episode OR have been unable to tolerate at least two separate trials of antidepressants at less than the minimum adequate dose and/or duration (ATHF 1 or 2);
  7. have a score ≥ 18 on the Hamilton Depression Rating Scale (HDRS-17 item);
  8. have had no increase or initiation of any psychotropic medication in the 4 weeks prior to screening;
  9. are able to adhere to the treatment schedule;
  10. pass the TMS and MRI adult safety screening questionnaires.
Exclusion Criteria
  1. have a history of substance use within the last 3 months;
  2. have a concomitant major unstable medical illness;
  3. have active suicidal intent;
  4. are pregnant;
  5. have a lifetime (MINI) diagnosis of any psychotic or bipolar disorder;
  6. have a MINI anxiety disorder or personality disorder assessed by a study investigator to be primary and causing greater impairment than MDD;
  7. have failed a course of ECT in the current episode;
  8. have any significant neurological disorder, any history of seizure (except those therapeutically induced by ECT), significant head trauma with loss of consciousness for > 5 min;
  9. have any intracranial implant (e.g., aneurysm clips) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed;
  10. are participating in psychotherapy, must have been in stable treatment for at least 3 months prior to study entry, with no anticipated change in the frequency of therapeutic sessions, or focus of therapeutic sessions over the duration of the study;
  11. have a clinically significant laboratory abnormality, in the opinion of the one of the principal investigators;
  12. have a non-correctable clinically significant sensory impairment (i.e., cannot hear well enough to cooperate with interview);

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Low Frequency Right (LFR)Low Frequency Right (LFR)1Hz stimulation to the R-DLPFC
Intermittent Theta Burst Stimulation (iTBS)Repetitive Transcranial Magnetic StimulationiTBS to the L-DLPFC
Intermittent Theta Burst Stimulation (iTBS)Intermittent Theta Burst Stimulation (iTBS)iTBS to the L-DLPFC
Low Frequency Right (LFR)Repetitive Transcranial Magnetic Stimulation1Hz stimulation to the R-DLPFC
Primary Outcome Measures
NameTimeMethod
Depression severity30 days

17 item Hamilton Depression Rating Scale (HDRS-17) Change

Secondary Outcome Measures
NameTimeMethod
Depression severity30 days

Self-rated 16-item Quick Inventory of Depressive Symptoms (QIDS-16) Change

Suicidal ideation30 days

Columbia Suicide Severity Rating Scale Screen Version (C-SSRS) Change

Anxiety severity30 days

Hamilton Anxiety Rating Scale (HAM-A) Change

Trial Locations

Locations (2)

Centre for Addiction and Mental Health

🇨🇦

Toronto, Ontario, Canada

Non-Invasive Neurostimulation Therapies Centre, University of British Columbia

🇨🇦

Vancouver, British Columbia, Canada

© Copyright 2025. All Rights Reserved by MedPath